The Usefulness of Biological and Neuroimaging Markers for the Diagnosis of Early-Onset Alzheimer's Disease

The recent proposed criteria for Alzheimer's Disease (AD) have strongly claimed the usefulness of biological and neuroimaging markers for early identification AD. Cerebrospinal fluid (CSF) Tau/Abeta ratio, hippocampal atrophy, posterior cingulate, and neocortical associative area hypometabolism, or amyloid burden evaluated by PiB compound, held the premises to increase diagnostic accuracy in the preclinical disease stages. Despite many efforts to identify subjects at risk of developing AD, less attention has been paid to presenile AD diagnosis. A few data are already available in early onset AD, mainly obtained in cases of monogenic disorder. In this paper, we discuss the current literature on the role of biological and neuroimaging markers in presenile AD.

[1]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[2]  D. Perani,et al.  Dementia, delusions and seizures: storage disease or genetic AD? , 2007, European journal of neurology.

[3]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[4]  D. Mann,et al.  Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. , 2001, The American journal of pathology.

[5]  P. S. St George-Hyslop,et al.  Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. , 2000, Archives of neurology.

[6]  M. Barcikowska,et al.  Early-onset Alzheimer's disease with a de novo mutation in the presenilin 1 gene , 2007, Experimental Neurology.

[7]  S. M. Sumi,et al.  Phenotype of chromosome 14–linked familial Alzheimer's disease in a large kindred , 1994, Annals of neurology.

[8]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[9]  C. van Broeckhoven,et al.  Presenilin mutations in Alzheimer's disease , 1998, Human mutation.

[10]  Nick C Fox,et al.  Chromosome 14 familial Alzheimer’s disease: the clinical and neuropathological characteristics of a family with a leucine→serine (L250S) substitution at codon 250 of the presenilin 1 gene , 1998, Journal of neurology, neurosurgery, and psychiatry.

[11]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[12]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[13]  J. Hardy,et al.  An Iranian family with Alzheimer's disease caused by a novel APP mutation (Thr714Ala). , 2002, Neurology.

[14]  Eric Westman,et al.  Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation , 2011, Neurobiology of Aging.

[15]  R. Nitsch,et al.  High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. , 2000, American journal of human genetics.

[16]  D. Campion,et al.  INTRAFAMILIAL DIVERSITY OF PHENOTYPE ASSOCIATED WITH APP DUPLICATION , 2008, Neurology.

[17]  D. Pollen,et al.  Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline , 2005, Neurology.

[18]  I. Siegert,et al.  Presenilin-1–associated abnormalities in regional cerebral perfusion , 2001, Neurology.

[19]  Benson Df.  The spectrum of dementia: a comparison of the clinical features of AIDS/dementia and dementia of the Alzheimer type. , 1987 .

[20]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[21]  Karalyn Patterson,et al.  Clinical and pathological characterization of progressive aphasia , 2006, Annals of neurology.

[22]  M. Cruts,et al.  Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. , 2001, Brain : a journal of neurology.

[23]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[24]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[25]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[26]  V. Blanchard,et al.  Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1 , 2002, Neuroscience Letters.

[27]  Nilüfer Ertekin-Taner,et al.  Genetics of Alzheimer's disease: a centennial review. , 2007, Neurologic clinics.

[28]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[29]  A. Goate,et al.  Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Aβ 42/40 ratios , 2005, Journal of neurochemistry.

[30]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[31]  P. S. St George-Hyslop,et al.  Molecular genetics of Alzheimer's disease: the role of β-amyloid and the presenilins , 2000, Current opinion in neurology.

[32]  T. Iwatsubo.  Aβ42, Presenilins, and Alzheimer’s Disease , 1998, Neurobiology of Aging.

[33]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[34]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[35]  J. Kira,et al.  A novel mutation (L250V) in the presenilin 1 gene in a Japanese familial Alzheimer's disease with myoclonus and generalized convulsion , 2003, Journal of the Neurological Sciences.

[36]  Stefan J. Teipel,et al.  Novel MRI techniques in the assessment of dementia , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  C. Cotman,et al.  Clinical and pathological evidence for a frontal variant of Alzheimer disease. , 1999, Archives of neurology.

[39]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[40]  Kiralee M. Hayashi,et al.  The topography of grey matter involvement in early and late onset Alzheimer's disease. , 2007, Brain : a journal of neurology.

[41]  D. Benson.  The spectrum of dementia: a comparison of the clinical features of AIDS/dementia and dementia of the Alzheimer type. , 1987, Alzheimer disease and associated disorders.

[42]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[43]  P. Lantos,et al.  Alzheimer's Disease Families with Amyloid Precursor Protein Mutations a , 1993, Annals of the New York Academy of Sciences.

[44]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[45]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[46]  Nick C Fox,et al.  Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.

[47]  M. Anagnostouli,et al.  Novel mutations and repeated findings of mutations in familial Alzheimer disease , 2005, Neurogenetics.

[48]  M. Verbeek,et al.  CSF studies facilitate DNA diagnosis in familial Alzheimer's disease due to a presenilin-1 mutation. , 2009, Journal of Alzheimer's disease : JAD.

[49]  James B Leverenz,et al.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.

[50]  J. Wegiel,et al.  A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. , 2004, Journal of Alzheimer's disease : JAD.

[51]  F. Mottaghy,et al.  A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer’s disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF , 2010, European journal of neurology.

[52]  K Patterson,et al.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.

[53]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[54]  Majaz Moonis,et al.  Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.

[55]  K. Nakashima,et al.  A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis , 2004, Neuroscience Letters.

[56]  H. Soininen,et al.  Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions , 1995, Journal of neural transmission. Parkinson's disease and dementia section.

[57]  M N Rossor,et al.  Atrophy of the Hippocampal Formation in Early Familial Alzheimer's Disease , 1996, Annals of the New York Academy of Sciences.

[58]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.